This morning, Deirdre Connelly, GlaxoSmithKline's President of North America Pharmaceuticals, gave an important speech at the Center for Business Intelligence 8th Annual Pharmaceutical Compliance Conference in Washington, D.C.
In her speech to 350 healthcare compliance executives, consultants and attorneys, Deirdre addressed head-on the pharmaceutical industry's failure to always fully appreciate the evolving expectations of our stakeholders.
In outlining her views on what both our company and industry must do to regain the position of trusted contributor and provider of healthcare, she emphasized that we must first start with a core set of values that go beyond just compliance with laws and regulations. At GSK, those values are:
§ focusing on what is in the best interests of patients
§ being transparent about working relationships
§ operating with integrity
§ respecting those we work with and serve
Putting these values into practice, Deirdre contends, means those in healthcare must be willing to "break the mold" and conduct business differently; it must commit resources to make values part of the organizational culture; and leaders must continue to challenge themselves and their organizations to keep pace with the needs of those they serve.
In her speech she cited examples of how GSK has taken on that agenda and is transforming the way we do business to meet the expectations of healthcare providers and patients. As examples, she described how we are voluntarily reporting payments it makes to healthcare providers for speaking and consulting. She relayed how GSK has changed our funding of continuing medical education and that we now only support CME for non-profit organizations and how we are moving away from providing bonuses for our sales representatives based on prescription volumes.
Click here to check out the full text of the speech